Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Common Equity (2020 - 2025)

Historic Common Equity for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $46.6 million.

  • Mereo BioPharma's Common Equity fell 3575.88% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 3575.88%. This contributed to the annual value of $61.0 million for FY2024, which is 2064.23% up from last year.
  • Mereo BioPharma's Common Equity amounted to $46.6 million in Q3 2025, which was down 3575.88% from $54.2 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma's Common Equity ranged from a high of $118.6 million in Q4 2021 and a low of $42.8 million during Q1 2024
  • Moreover, its 5-year median value for Common Equity was $60.5 million (2024), whereas its average is $69.7 million.
  • Per our database at Business Quant, Mereo BioPharma's Common Equity surged by 70008.5% in 2021 and then plummeted by 5666.95% in 2022.
  • Mereo BioPharma's Common Equity (Quarter) stood at $118.6 million in 2021, then crashed by 56.67% to $51.4 million in 2022, then fell by 1.68% to $50.5 million in 2023, then increased by 20.64% to $61.0 million in 2024, then fell by 23.57% to $46.6 million in 2025.
  • Its last three reported values are $46.6 million in Q3 2025, $54.2 million for Q2 2025, and $60.1 million during Q1 2025.